Steroid-induced rosacea in systemic lupus erythematosus
DOI:
https://doi.org/10.66344/jpad.v33i1.2011Abstract
Rosacea is identified with erythema of the central face with flushing, papules, pustules, and telangiectasia. It is induced by chronic, repeated exposure to triggers such as sunlight, temperature, exercise, menopausal flushing, cosmetics, medications, spicy food, emotions, liquor, and topical irritants. A 59-year-old female visited a dermatology and venereology outpatient clinic with redness and flushing all over the facial area for more than one year which is worsening. The previous diagnosis was systemic lupus erythematosus, treated with topical corticosteroids for the last one year, but there was no clinical improvement. The patient was currently diagnosed with rosacea based on the erythematous facial lesion and multiple discrete telangiectasias. The lesion improvement was shown after one month of treatment with topical metronidazole 0,75%, topical nicotinamide 4%, and topical tretinoin 0,025%, and tapered off the use of topical corticosteroids. Rosacea commonly mimics many diseases, including photosensitivity in lupus erythematosus. The initial usage of steroids results in clearance of the primary lesion. However, continuous usage causes atrophy of epidermis, degeneration of dermal structure, and deterioration of collagen, leading to rosacea with a scaly, flaming red, and papule-covered face. Other diagnoses and treatments must be considered if, after years of corticosteroid treatment, demonstrate no improvement. Rosacea with facial erythema as a common presentation is very challenging to diagnose. Careful clinical judgments and considerations of therapy must be made before giving long-term corticosteroid therapy due to the possible following adverse effect such as steroid-induced rosacea.
References
1. Steinhoff M, Buddenkotte J. Rosacea. In: Kang S, Amagai M, Bruckner A, Enk A, Margolis D, McMichael A, editors. Fitzpatrick’s Dermatology. 9th ed. McGraw-Hill Education; 2019. p. 1419.
2. Kizoğlu G. Red face revisited: Flushing. Clinics in Dermatology. 2014; 32: 800–808.
3. Izıkson L, English JC, Zirwas MJ. The flushing patient: Differential diagnosis, workup, and treatment. J Am Acad Dermatol. 2006;55:193-208.
4. Johnson SM, Berg A, Barr C. Managing Rosacea in the Clinic: From Pathophysiology to Treatment-A Review of the Literature. J Clin Aesthet Dermatol. 2020;13(4 Suppl):S17-S22.
5. Gallo RL, Granstein RD, Kang S, et al. Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2017;78:148-55.
6. Draelos ZD. Cosmetics in rosacea. In: Zouboulis CC, Katsambas AD, Kligman AM, eds. Pathogenesis and Treatment of Acne and Rosacea. New York, NY: Springer; 2014. p. 717-27.
7. Zhang H, Tang K, Wang Y, Fang R, Sun Q. Rosacea Treatment: Review and Update. Dermatol Ther (Heidelb). 2021;11(1):13-24.
8. Hameed AF. Steroid dermatitis resembling rosacea: a clinical evaluation of 75 patients. ISRN Dermatol. 2013;21:491376.
9. Dessinioti Clio, Antoniou Christina. The “red face”: Not always rosacea. Clin Dermatol. 2017;35:201-6.
10. Rezaković Saida, Mokos Zrinka Bukvić, Paštar Zrinjka. Drug-Induced Rosacea-like Dermatitis. Acta Dermatovenerol Croat. 2016;24(1):49-54.
11. Bhat YJ, Manzoor S, Qayoom S. Steroid-induced rosacea: a clinical study of 200 patients. Indian J Dermatol. 2011;56:30-2.
12. Rathi SK, Kumrah L. Topical corticosteroids-induced rosacea-like dermatitis: a clinical study of 110 cases. Indian J Dermatol Venereol Leprol. 2011;77:42-6.
13. Sneddon I. Adverse effect of topical fluorinated corticosteroids in rosacea. Br Med J. 1969;1:671-3.
14. Miyachi Y, Yamasaki K, Fujita T, Fujii C. Metronidazole gel (0.75%) in Japanese patients with rosacea: a randomized, vehicle-controlled, phase 3 study. J Dermatol. 2021:49(3):330-40.
15. Searle T, Al-Niaimi F, Ali FR. Rosacea. Br J Hosp Med. 2021;82(2):1-8.
16. Rofle HM. A review of nicotinamide: treatment of skin diseases and potential side effects. J Cosmet Dermatol. 2014:13;325.
17. Engin B, Özkoca D, Kutlubay Z, Serdaroğlu1 S. Conventional and Novel Treatment Modalities in Rosacea. Clin Cosmet Investig Dermatol. 2020;13:179-86.
18. Anzengruber F, Czernielewski J, Conrad C, Feldmeyer L, Yawalkar N, Häusermann P, et al. Swiss S1 guideline for the treatment of rosacea. J Eur Acad Dermatol Venereol. 2017;31(11):1775-91.
19. van Zuuren EJ, Fedorowicz Z, Tan J, et al. Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. Br J Dermatol. 2019;181(1):65-79.
20. Li G, Wang B, Zhao Z, et al. Excessive cleansing: an underestimating risk factor of rosacea in Chinese population. Arch Dermatol Res. 2021;313(4):225-34.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Windy Keumala Budianti, Nevi Yasnova, Arlha Aporia Debinta, Shafira Anindya
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
